• 1.昆明醫(yī)學(xué)院第一附屬醫(yī)院普通外科（昆明650032）;;
  • 2.浙江省蒼南縣第三人民醫(yī)院普通外科（蒼南325800）;;
  • 3.昆明醫(yī)學(xué)院第一附屬醫(yī)院實(shí)驗(yàn)中心;

目的 探討槐耳清膏在體外對(duì)人直腸癌HR8348細(xì)胞的生長(zhǎng)抑制作用和凋亡誘導(dǎo)作用及其作用機(jī)理。方法 將處于對(duì)數(shù)生長(zhǎng)期的HR8348細(xì)胞用含槐耳清膏的培養(yǎng)基培養(yǎng)36 h，用四氮唑藍(lán)（MTT）比色法檢測(cè)吸光度(OD)值，計(jì)算抑制率； 用甲基綠-派若寧染色法及TUNEL法檢測(cè)細(xì)胞凋亡指數(shù)； 用免疫組織化學(xué)方法檢測(cè)bcl-2、bcl-xl、bax、bak及p53基因表達(dá)的情況。結(jié)果 槐耳清膏對(duì)HR8348細(xì)胞的抑制率隨濃度增加而上升，濃度為4.0 mg/ml時(shí)抑制率最大（71.1%），與5-FU組（濃度為10 μg/ml）相比差異無(wú)顯著性意義（P＞0.05）。甲基綠-派若寧染色法和TUNEL法均可見到典型的細(xì)胞凋亡、凋亡小體或出泡現(xiàn)象，凋亡指數(shù)隨槐耳清膏濃度的增加而增加，當(dāng)濃度達(dá)4.0 mg/ml時(shí)，凋亡指數(shù)迅速上升，甲基綠-派若寧法為0.1620±0.0128，TUNEL法為0.2612±0.0158，均大于5-FU組的凋亡指數(shù)（0.0780±0.0095和0.1028±0.0131），P＜0.05?；倍甯嘟Mbcl2、bclxl、bak、p53蛋白表達(dá)較空白對(duì)照組明顯增強(qiáng)（P＜0.05)，而bax變化不明顯（P＞0.05）?；倍甯嘟Mbak/bcl-2 和bak/bcl-xl比值顯著大于空白對(duì)照組。結(jié)論 槐耳清膏在體外對(duì)人直腸癌HR8348細(xì)胞具有顯著的抑制作用和凋亡誘導(dǎo)作用。槐耳清膏誘導(dǎo)人直腸癌HR8348細(xì)胞凋亡可能與提高bak/bcl-2、bak/bcl-xl比值及上調(diào)p53基因表達(dá)有關(guān)。

引用本文： 程若川,湯禮貴,蘭麗琴,賈偉. 槐耳清膏誘導(dǎo)人直腸癌HR8348細(xì)胞凋亡的實(shí)驗(yàn)研究. 中國(guó)普外基礎(chǔ)與臨床雜志, 2003, 10(6): 568-571. doi: 復(fù)制

1. 姜泊主編. 細(xì)胞凋亡基礎(chǔ)與臨床 [M].第1版. 北京： 人民軍醫(yī)出版社， 1999∶257～258.
2. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl2 and p53 oncoprotein expression during colorectal tumorigenesis [Ｊ]. Cancer Res, 1995; 55(2)∶237.
3. Cheng EH, Wei MC, Weiler S, et al. BCL2, BCLx（L） sequester BH3 domainonly molecules preventing bax and bakmediated mitochondrial apoptosis [Ｊ].Mol Cell, 2001; 8(3)∶705.
4. Oh SJ, Im MY. The p53 mutation which abrogates transactivation while maintaining its growthsuppression activity [Ｊ]. Mol Cells, 2000; 10(4)∶386.
5. Kaneuchi M, Yamashita T, Shindoh M, et al. Induction of apoptosis by the p53-273L (Arg→Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax [Ｊ].Mol Carcinog, 1999; 26(1)∶ 44.
6. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation [Ｊ]. Ann N Y Acad Sci, 2000; 910∶121.
  1. 1. 姜泊主編. 細(xì)胞凋亡基礎(chǔ)與臨床 [M].第1版. 北京： 人民軍醫(yī)出版社， 1999∶257～258.
  2. 2. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl2 and p53 oncoprotein expression during colorectal tumorigenesis [Ｊ]. Cancer Res, 1995; 55(2)∶237.
  3. 3. Cheng EH, Wei MC, Weiler S, et al. BCL2, BCLx（L） sequester BH3 domainonly molecules preventing bax and bakmediated mitochondrial apoptosis [Ｊ].Mol Cell, 2001; 8(3)∶705.
  4. 4. Oh SJ, Im MY. The p53 mutation which abrogates transactivation while maintaining its growthsuppression activity [Ｊ]. Mol Cells, 2000; 10(4)∶386.
  5. 5. Kaneuchi M, Yamashita T, Shindoh M, et al. Induction of apoptosis by the p53-273L (Arg→Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax [Ｊ].Mol Carcinog, 1999; 26(1)∶ 44.
  6. 6. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation [Ｊ]. Ann N Y Acad Sci, 2000; 910∶121.